KOMET-007: Bringing Menin Inhibition Into Frontline AML Care

In an interview with Targeted Oncology, Amer Zeidan, MBBS, MHS, chief, division of hematologic malignancies at Yale Cancer Center and professor of medicine at Yale School of Medicine, discusses the rationale, design, and patient population of the phase 1b/2 KOMET-007 trial (NCT05735184) evaluating ziftomenib (Komzifti) in combination with standard therapies for newly diagnosed acute myeloid leukemia (AML), the updated data of which were presented this month at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden.

Zeidan outlines the scientific rationale for combining ziftomenib with standard-of-care regimens, including intensive induction chemotherapy with 7+3 and the lower-intensity regimen of azacitidine plus venetoclax (Venclexta). He also reviews the development of menin inhibitors in AML, including recent regulatory advances in the relapsed/refractory setting, and explains why investigators sought to move this therapeutic approach into earlier lines of treatment.

Zeidan further describes the design of KOMET-007, including patient eligibility criteria, treatment sequencing, dosing strategy, and maintenance therapy considerations. The study enrolled patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML and evaluated ziftomenib in combination with established treatment backbones. He also provides context on the characteristics of the enrolled population and how they compare with patients commonly seen in clinical practice.